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Abstract 
Background: 
Given that the burden of cancer is set to increase globally, strategies are needed to 
improve the early detection of cancer.  As such, increasing focus is now placed on 
promoting the early detection of cancer through education and screening 
interventions.  One healthcare setting that has significant potential in delivering these 
approaches is the community pharmacy.   
Aims: 
This study aimed to systematically review the literature to identify and assess the 
current evidence for the role of community pharmacies in delivering early cancer 
detection initiatives.   
Method: 
A systematic literature search of four databases was undertaken (Medline, Embase, 
CINAHL, PsycINFO) from inception to February 2015 to identify peer-reviewed 
intervention studies.   
Results: 
A total of 2772 articles were identified from the search, of which ten were included in 
the review.  The studies focused on a range of different cancers and showed it is 
feasible to recruit patients to education and screening interventions within a 
community pharmacy setting.  However, the interventions were poorly described in 
the literature.   
Conclusion: 
Formatted: Underline
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There is significant potential for community pharmacy to deliver education and 
screening-based interventions to promote the early detection of cancer, but more 
evidence is needed to ascertain how interventions delivered in this setting impact on 
the outcome for patient outcomess in terms of survival. 
Key words: early detection, cancer, community pharmacy, screening, intervention. 
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Introduction 
Early detection of cancer significantly improves the probability of a better survival 
outcome [1].  For example, 5-year survival rates for early stage non-small cell lung 
cancer (NSCLC) are around 50 times higher compared with late stage disease [2]. 
Given the ageing population, and that the cancer burden is set to increase globally [3], 
strategies are needed to improve the early detection of cancer.  This challenge is 
acknowledged by the World Health Organization (WHO) [4], which has adopted a 
series of strategies to promote early cancer detection. One approach is developing 
interventions to raise public awareness through education regarding early warning 
signs of cancer (e.g. a mole that has recently changed), while another relates to cancer 
screening: typically individuals from healthy populations are tested to identify those 
who have previously undetected cancer but, as yet, do not exhibit any symptoms. 
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One healthcare setting that potentially has a role in providing both of these early 
detection approaches is the community pharmacy. Indeed, the WHO has 
acknowledged that community pharmacists are the most accessible healthcare 
professionals to the general public [5]. Studies have shown that community 
pharmacies offer easy and equitable access to healthcare [6, 7] with estimates that, in 
the UK, 8490 per cent of the population make at least one visit in the course of a year. 
Community pharmacies, therefore, appear to be uniquely placed to raise awareness of 
and screen for cancer.  Work has shown people present at community pharmacies 
seeking care for symptoms which could be indicative of early signs of cancer [8], yet, 
despite this potential, there is no comprehensive review of the role and contribution of 
community pharmacies in early cancer detection. 
                                                 
1
 EPOC (Effective Practice and Organisation of Care Group), EPHPP (Effective Public Health 
Practice Project), TIDieR (Template for Intervention Description and Replication), Faecal 
occult blood (FOB), Prostate specific antigen  (PSA) 
Comment [AT1]: Cite White paper in 
England. 
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This study aimed to systematically review the literature to identify and assess the 
current evidence for the role of community pharmacies in delivering early cancer 
detection initiatives 
Methods 
Sources 
The following electronic databases were searched to identify evidence: MEDLINE 
(Ovid), EMBASE (Ovid), CINAHL (EbscoHost) and PsycINFO (EbscoHost).  The 
search period was from inception of the databases to February 2015. The terms used 
in the search strategy were related to cancer, community pharmacy and intervention 
(Appendix 1). The search strategy was modified when appropriate to suit syntax 
requirements; no MeSH terms were used.  No limit was placed on study type, 
publication, date and language in the search strategy. The reference lists of the 
included studies were hand searched to identify relevant studies.   
The review was designed and carried out following established guidelines on good 
conduct and reporting of systematic reviews[9, 10]; the protocol was registered with 
PROSPERO [11], registration number 2014:CRD42014009092. 
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Study selection 
To be included in the review, studies had to meet the following criteria:  
1. Setting: include or take place within a community pharmacy. In this 
review community pharmacy was defined as pharmacy that is based in the 
community (not in a hospital, clinic or online) and is accessible to all; 
2. Population: the general public accessing a cancer education or screening 
intervention;   
3. Study type: all study types were included; 
4. Intervention: patient- focused cancer education and raising awareness over 
early cancer symptoms, cancer screening and/or detection; 
5. Outcomes: study outcomes were conceptualised in accordance with the 
framework proposed by Hardeman et al[12]. This framework contains four 
categories: determinants of behaviour (e.g. increased patient knowledge), 
behavioural outcomes (e.g. reducing exposure to cancer risk factors), 
physiology and biochemical outcomes (identification of patients with pre-
malignant disease) and health outcomes (incidence rates of cancer). 
Any study that was not set in a community pharmacy was excluded from the review 
(e.g. a pharmacist working in an outpatient clinic).  Interventions that solely sought to 
educate the community pharmacy team about cancer awareness or did not specifically 
include patients were also excluded.  Studies that were reported as abstracts were also 
excluded from the review.  
The initial screening of search titles and abstracts was undertaken by one 
researcher(LL) with a ten per cent sample checked by a second researcher(AT); any 
disagreement was discussed and, if agreement could not be reached, consensus was 
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reached with a third researcher(AH).  The full text version of selected studies were 
independently screened for by two researchers(LL, AT); data extraction was done 
independently by two researchers (LL, HN) using a template based on the EPOC data 
extraction form[13]. Differences in data extraction were resolved through discussion 
and, if consensus was not reached, the project lead was consulted(AT). 
Results 
Literature search 
In total 2772 articles were identified, 2767 hits were generated through database 
searches and further five articles were identified through hand search. After duplicates 
were removed, 2451 studies were screened based on title.  Of these, 644 were 
screened for both title and abstract, which resulted in a full paper screen of 32 articles.  
In total, ten articles were included in the review (Figure 1). 
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Figure 1: PRISMA diagram showing study selection 
Analysis 
The studies identified for the review were strongly heterogeneous, thus, it was not 
feasible to pool results and undertake a meta-analysis.  A narrative approach to 
synthesising the results was adopted. The data used for the synthesis included: type of 
cancer, study design, population, location, study objectives, outcome measures and 
outcomes. The categories listed in the TIDieR recommendations for better reporting 
of interventions, were used to summarise the interventions described in the studies 
[14].   
 
 
5 articles identified 
through hand 
search of 
reference lists 
Articles identified 
from databases: 
MEDLINE 614 
EMBASE 1528 
CINAHL 232 
PsychInfo 393 
2451 study titles 
screened for 
eligibility 
321 duplicates 
644 articles 
identified for 
abstract review 
1807 studies excluded not 
relevant to the topic 
612 studies excluded 
32 articles 
identified for full 
review 
10 studies 
included 
Abstract (n=6) 
Intervention not aimed at 
patients (n=4) 
No results presented (n=1) 
Not an intervention (n=7) 
Opinion piece (n=2) 
Prospective study (n=2) 
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Quality appraisal 
The studies were assessed for quality using the EPHPP Quality Assessment Tool for 
Quantitative Studies [15] recommended by Cochrane.  The global quality scores, 
based on the individual component scores, divided the studies to strong (n=1) [16], 
moderate (n=5) [17-21] and weak (n=4) [22-25]. The study components most 
commonly assessed as weak were confounders and the data collection methodology. 
 
Description of studies 
Ten studies were included in the review, these are described in Table 1. The studies 
were categorised according to the chart of study types for inclusion in EPOC reviews 
[26]; one was a randomised controlled trial [21], one was a cluster randomised trial 
[24], one was a non-randomised trial [22] and the remainder were non-comparative 
studies [16-20, 23, 25].  
Study locations were the US (n=5) [17-20, 24], Australia (n=2) [22, 23], Germany 
(n=1)[16], Italy (n=1)[21] and South Korea(n=1) [25]. The number of participants 
included in the studies ranged from 91 [23] to 14,041 [21], while the duration 
including follow up ranged from four weeks [19] to two years [16].  
Cancer types 
Types of cancer targeted by the studies included colorectal cancer (n=4) [19, 22-24]; 
colorectal and prostate cancer (n=1) [17]; prostate cancer (n=1) [16]; breast cancer 
(n=2) [18, 25]; cervical cancer (n=1) [21]; and breast and cervical cancer (n=1) [20, 
21].  
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Participants 
The total number of participants in the studies was 25,449, ranging from 91 [23] to 
14,041 [21]. Four of the studies were aimed exclusively at women (those for breast 
and cervical cancer), two at men (those for prostate cancer) and four at both sexes.  
Three of the studies targeted specific populations: one focused on women living in 
medically underserved communities [20], one on women who were non-responders to 
a screening invitation [21], and one on men with untreated or uncontrolled health 
risks or who were due a physical examination [17]. 
Study outcomes 
The Hardeman causal model was used to categorise the outcomes [12]. All ten studies 
reported outcome measures relating to the domain of behavioural determinants; 
increasing awareness and knowledge (n=7) [16-20, 24, 25]; recommending referral 
(n=3) [21-23].  Outcomes of four studies were identified as influencing patient’s 
behavior [16, 17, 19, 20].  Physiological and biochemical outcomes were measured in 
four studies (FOB n=2 [19, 24], PSA n=1 [16], Pap/HPV DNA n=1 [21]) and health 
outcomes (cancer diagnosis) in two [16, 19]. 
Educational interventions 
Four of the studies were aimed at educating the patients [18, 20, 24, 25]. Of these, 
three were specifically focused on educating women about breast and ovarian cancer. 
These included a city wide education programme focusing on reducing breast cancer 
‘myths’ [25] and a community intervention to increase the uptake of screening for 
breast and ovarian cancer in medically underserved areas [20]. Third study provided 
education and training on breast self-examination (BSE), clinical breast examination 
(CBE) and mammograms, and provided risk assessment screening [18]. The fourth 
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study, on colorectal cancer, compared the outcomes between providing patients 
educational handouts and advice or giving patients FOB test kits [24]. 
Screening interventions 
Eight of the studies undertook screening [16-19, 21-24]. Four of the studies used test 
kits, of which, two were FOB tests [19, 24], one was a PSA blood test [16] and one 
used Pap and HPV DNA tests [21]. Three of these studies were  large scale screening 
programmes (n=2,119 [16], n=7,794 [19], n=14,041 [21]) and one was a smaller pilot 
(n=133) [24].  
Four studies provided screening through questionnaires or checklists [17, 22-24]. All 
the screening tools were previously validated or were constructed from previously 
validated instruments. The Patient Consultation Questionnaire (PSQ) [27], for 
identifying patients at risk of colorectal cancer, was used by two of the studies [22, 
23], while a Breast Cancer Risk Assessment Tool (Gail model) [28] was used in one 
study.  Another study combined a number of existing tools, including assessments for 
prostate cancer [29] and colorectal cancer [30], to form a Men’s Health Risk 
Assessment Tool (MHRAT) [17]; however, this tool was not checked for validity or 
reliability.  
Three studies identified patients at increased risk of various developing cancers [17, 
18, 23]. The study utilising the MHRAT assessed 40 per cent of participants to be at 
risk of developing prostate cancer and 24 per cent at risk of colon cancer [17]. 
Similarly, a breast cancer education and screening intervention found 15 per cent of 
the participants to be at increased risk of developing breast cancer [18], whilst a 
screening study for bowel cancer found that 8.7 per cent of those presenting at 
community pharmacies with bowel symptoms were high risk [23].  
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Two studies identified the percentage of people attending a follow up appointment 
after receiving an initial positive screening test result (23.4% for PSA test [16], 59% 
for FOB test [19]).  For the studies using screening tools, the percentage of 
participants who acted on the recommendation of a referral ranged from 8.8 per cent 
[23] to 48.7 per cent [17]. 
Cancer detection 
A study using a FOB test for colorectal cancer reported one abnormal test result; no 
further details on diagnosis was given [24]. The cervical screening RCT compared 
posting self-sampling tests to non-responders and making the tests available through 
community pharmacies with the standard practice of a reminder letter; however, the 
test results were presented together for both of the experimental conditions, therefore 
it is not known how many of the test kits distributed through pharmacies had a 
positive test result [21]. Two other studies followed patients throughout the screening 
process to confirm or exclude a cancer diagnosis.  In a prostate screening study, 
involving all 28 pharmacies in the city, 15 per cent of the PSA test results were 
positive (PSA >4.0ng/ml) [16] and prostate carcinoma was confirmed in 14 cases, 
corresponding to an incidence rate of 650 cases per 100,000 men tested. In a 
colorectal cancer screening, of the 1337 participants assessed as high risk, 23 (2%) 
were diagnosed with colorectal cancer, of which 20 were early stage [19].  
 
Discussion 
This review presents the available evidence on using community pharmacies as a 
setting to deliver early cancer detection interventions through screening and 
education. The review shows, it is possible to recruit patients to such interventions 
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through a community pharmacies, and to identify patients who are at an increased risk 
of developing cancer. These findings are timely, as recent draft NICE guidance 
acknowledges thousands of people die every year because of a late cancer diagnosis 
and thus recommends more people should be referred for cancer testing[31]. Our 
results suggest that community pharmacies could make a significant contribution to 
this activity.  The potential for increasing community pharmacy involvement in this 
area has been noted by an early detection collaboration (the ACE programme), which 
seeks to increase the evidence base around the best practice in early detection, and 
one of the activity clusters specifically focuses on pharmacy-led initiatives[32]. 
Due to the heterogeneity of the study outcomes, performing a meta-analysis was not 
possible; we were limited to reporting our findings as a narrative synthesis and 
acknowledge this as a limitation of our review.  Also, as we restricted our review to 
interventional studies, qualitative studies examining participants’ views on using 
community pharmacies for such interventions, were excluded.  Clearly, for patients to 
engage in early cancer detection interventions within community pharmacy settings, it 
is important that they are perceived as worthwhile, appropriate and valuable. 
However, even though the selection criteria for the review were specifically for 
interventional studies, some of the studies did include a qualitative aspect and 
indicated a positive perceptiongood reception of the amongst the participants towards 
community pharmacy based interventions. One study surveyed participants’ 
perceptions as part evaluating the screening intervention, finding that the participants 
were enthusiastic about receiving colorectal cancer education and screening from 
community pharmacists, as they felt that pharmacies were a trustworthy source of 
information[24]. Another study reported increased confidence levels amongst 
participants in their ability to perform a breast self-examination following the 
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pharmacy intervention[18]. Furthermore, previous qualitative work has shown that, in 
the context of wider public health initiatives, patients view community pharmacists as 
appropriate providers of such services and, of those that accessed such services, 
satisfaction levels were found to be high[33]. 
In the light of the demand to increase community pharmacy involvement in the 
delivery of wider public health services[6, 34-37], there is a growing body of 
literature in this area.  Indeed a relatively recent systematic review[38] exploring the 
role of community pharmacies in screening for major diseases concluded it is feasible 
to screen patients in this setting, but more studies were needed to ascertain the 
effectiveness and economic benefit of such interventions; of note, this work only 
identified three studies that were included in our review. Nonetheless, our study 
supports this work, and shows that the community pharmacy is a feasible setting to 
deliver screening and educational interventions in relation to the early detection of 
cancer. 
Given the easy and equitable access of community pharmacies, it is possible that 
delivering early cancer interventions from community pharmacies could also 
potentially have an impact on health inequalities, with a recent study showing access 
to community pharmacies is greatest in areas of high deprivation – the so-called 
positive pharmacy care law [6]. Indeed, given the evidence that supports an inverse 
correlation between socioeconomic status and incidence and mortality of some 
cancers, cancer-related inequalities represent a significant challenge for current 
healthcare systems.  Generally, the studies identified in our review were aimed at the 
general public rather than specifically targeting patients from deprived communities; 
the socioeconomic status of patients’ accessing the interventions were not reported 
among the studies. One small-scale study did, however, focus on low and moderate 
Comment [AT2]: Laura: move this 
section to just before conclusion. 
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income women living in a medically underserved area and showed that community 
pharmacies could be used to identify patients at risk of breast and cervical cancer, and 
to refer them on for further investigation [20]. It is not clear if, or how, this study 
impacted on health inequalities or if this kind of intervention could be applied to 
initiatives for other cancers.  
Even though the outcomes of the interventions were encouraging, not enough details 
were given, to get a comprehensive understanding of the interventions that would 
allow for replication. In general, the practical elements of the interventions were 
poorly reported, especially in the areas of the delivery, education and fidelity. This 
lack of detail highlights the need for checklists, such as the TIDieR guide, developed 
by Hoffman and colleagues, to enable detailed reporting of interventions[14]. 
Assessing the interventions against the TIDieR categories, it was apparent that the 
mode of delivery, tailoring and details of modifications were not reported; 
information about the provider, including expertise, background and training were 
also limited. The quality and depth of reporting within the included studies is, at 
present, insufficient to enable others to effectively design and reproduce the 
interventions, which possibly has implications for the commissioning of future 
services in this area.  
None of the studies explicitly indicated a theoretical framework underpinning the 
design or delivery of the intervention.  This is not to say that the interventions were 
developed without thought, previous work in the area guided the development of the 
chosen approach. As many of the interventions were pilots, the focus was on the 
specific cancers and how screening and education had been undertaken in the past. 
However, taking the theoretical aspect into account when planning interventions, 
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would enable greater interplay between practice and theoretical evidence and the 
advancement of both through the recognition of their interdependent nature [39]. 
Beyond improving the reporting of interventions, there should also be more focus on 
capturing the impact of the studies in terms of actual benefit to patients.  On the 
whole, the included studies did not follow the participant through their care pathway 
and ascertain if a cancer diagnosis was made, and if it was made, the time taken to 
reach a diagnosis or how the intervention impacted on overall patient survival was not 
ascertained.  We do, however, acknowledge that several of the studies included within 
the review were not designed to follow up patients in terms of diagnosis or cancer-
related morbidity. Furthermore, it is also not understood whether interventions 
delivered through community pharmacies target a different patient group than what is 
currently being reached through other providers. In view of these limitations, further 
work in this area, exploring how such interventions affect the time taken to reach a 
cancer diagnosis or patient survival are warranted.  
Conclusion 
There is scope to use community pharmacies as a setting to deliver education and 
screening early cancer detection interventions.  Current evidence shows it is feasible 
to recruit patients in this setting, but more studies are warranted to demonstrate how 
these interventions impact on the time taken to reach a cancer diagnosis and patient 
outcome in comparison to other providers. 
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Appendix 1: An example search strategy used in the Medline Ovid platform 
1. Cancer 
2. Oncology 
3. (1 OR 2).ti,ab. 
4. Symptom 
5. Warning sign* 
6. Risk factor* 
7. Detect* 
8. Awareness 
9. Screen* 
10. Interven* 
11. Diagnos* 
12. Health promotion 
13. Prevent* 
14. (4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13).ti,ab. 
15. Community pharmac* 
16. Pharmacy 
17. Community pharmacy service* 
18. Pharmacist* 
19. Pharmaceutical service* 
20. Pharmacy assistant* 
21. Pharmacy technician* 
22. Medicine assistant* 
23. Counter assistant* 
24. (15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23).ti,ab. 
25. 3 AND 14 AND 24 
 
  
16 
 
References 
[1] Neal RD, Tharmanathan P, France B, Din NU, Cotton S, Fallon-Ferguson J, et al. 
Is increased time to diagnosis and treatment in symptomatic cancer associated 
with poorer outcomes? Systematic review. Br J Cancer. 2015;112 Suppl:S92-
s107. 
[2] American Cancer Society. Lung Cancer (Non-Small Cell). American Cancer 
Society; 2014. 
[3] Boyle P, Levin B. World Cancer Report 2008. Lyon: The World Health 
Organistion; 2008. 
[4] WHO. Cancer control: early detection. Geneva: WHO; 2007. 
[5] WHO. The Role of the Pharmacist in the Health Care System New Delhi1994. 
[6] Todd A, Copeland A, Husband A, Kasim A, Bambra C. The positive pharmacy 
care law: an area-level analysis of the relationship between community 
pharmacy distribution, urbanity and social deprivation in England. BMJ open. 
2014;4:e005764. 
[7] Todd A, Copeland A, Husband A, Kasim A, Bambra C. Access all areas? An 
area-level analysis of accessibility to general practice and community pharmacy 
services in England by urbanity and social deprivation. BMJ open. 
2015;5:e007328. 
[8] Badenhorst J, Todd A, Lindsey L, Ling J, Husband A. Widening the scope for 
early cancer detection: identification of alarm symptoms by community 
pharmacies. Int J Clin Pharm. 2015:1-6. 
[9] Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of 
Interventions Version 5.1.0. London: The Cochrane Collaboration; 2011. 
[10] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. 
The PRISMA statement for reporting systematic reviews and meta-analyses of 
studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 
2009;339:b2700. 
[11] Centre for Reviews adn Dissemination. International prospective register of 
systematic reviews. York: University of York; 2013. 
[12] Hardeman W, Sutton S, Griffin S, Johnston M, White A, Wareham NJ, et al. A 
causal modelling approach to the development of theory-based behaviour 
change programmes for trial evaluation. Health Education Research. 
2005;20:676-87. 
[13] Cochrane Effective Practice and Organisation of Care Review Group. Data 
collection checklist. Ottawa2002. 
[14] Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. 
Better reporting of interventions: template for intervention description and 
replication (TIDieR) checklist and guide2014. 
[15] Effective Public Health Practice Project. Quality assessment tool for 
quantitative studies. Hamilton: Effective Public Health Practice Project; 2009. 
[16] Berg W, Linder C, Eschholz G, Schubert J. Pilot study of the practical 
relevance of a one-step test for prostate-specific antigen in capillary blood to 
improve the acceptance rate in the early detection program of prostate 
carcinoma. International Urology and Nephrology. 2001;32:381-8. 
[17] Boyle TC, Coffey J, Palmer T. Men's health initiative risk assessment study: 
effect of community pharmacy-based screening. Journal of the American 
Pharmacists Association: JAPhA. 2004;44:569-77. 
17 
 
[18] Giles JT, Kennedy DT, Dunn EC, Wallace WL, Meadows SL, Cafiero AC. 
Results of a community pharmacy-based breast cancer risk-assessment and 
education program. Pharmacotherapy. 2001;21:243-53. 
[19] Levin B, Hess K, Johnson C. Screening for colorectal cancer: A comparison of 
3 fecal occult blood tests. Archives of Internal Medicine. 1997;157:970-6. 
[20] McGuire TR, Leypoldt M, Narducci WA, Ward K. Accessing rural populations: 
Role of the community pharmacist in a breast and cervical cancer screening 
programme. Journal of Evaluation in Clinical Practice. 2007;13:146-9. 
[21] Giorgi Rossi P, Fortunato C, Barbarino P, Boveri S, Caroli S, Del Mistro A, et 
al. Self-sampling to increase participation in cervical cancer screening: an RCT 
comparing home mailing, distribution in pharmacies, and recall letter. Br J 
Cancer. 2015;112:667-75. 
[22] Jiwa M, Sargant S, Hughes J, O'Connor M, Hodder R, Chan She Ping-Delfos W, 
et al. Triaging consumers who present bowel symptoms to community 
pharmacies: a pilot of two interventions. Australian Pharmacist. 2009;28:516-20. 
[23] Jiwa M, Sriram D, Khadaroo Z, Ping-Delfos WC. Could community 
pharmacies offer an opportunity to improve outcomes for patients with bowel 
cancer? Quality in Primary Care. 2011;19:105-8. 
[24] Potter MB, Gildengorin G, Wang Y, Wu M, Kroon L. Comparative 
effectiveness of two pharmacy-based colorectal cancer screening interventions 
during an annual influenza vaccination campaign. Journal of the American 
Pharmacists Association : JAPhA. 2010;50:181-7. 
[25] Park K, Hong WH, Kye SY, Jung E, Kim MH, Park HG. Community-based 
intervention to promote breast cancer awareness and screening: the Korean 
experience. BMC Public Health. 2011;11:468. 
[26] (EPOC). EPaOoC. What study designs should be included in an EPOC review 
and what should they be called? EPOC Resources for review authors. Oslo: 
Norwegian Knowledge Centre for the Health Services; 2014. 
[27] Smith D, Ballal M, Hodder R, Soin G, Selvachandran SN, Cade D. Symptomatic 
Presentation of Early Colorectal Cancer. Annals of The Royal College of Surgeons 
of England. 2006;88:185-90. 
[28] Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. 
Projecting individualized probabilities of developing breast cancer for white 
females who are being examined annually. Journal of the National Cancer 
Institute. 1989;81:1879-86. 
[29] von Eschenbach A, Ho R, Murphy GP, Cunningham M, Lins N. American 
Cancer Society guideline for the early detection of prostate cancer: update 1997. 
CA: a cancer journal for clinicians. 1997;47:261-4. 
[30] Byers T, Levin B, Rothenberger D, Dodd GD, Smith RA. American Cancer 
Society guidelines for screening and surveillance for early detection of colorectal 
polyps and cancer: Update 1997. CA: A Cancer Journal for Clinicians. 
1997;47:154-60. 
[31] National Collaborating Centre for Cancer. Suspected cancer: recognition and 
management of suspected cancer in children, young people and adults. London: 
National Institute for Health and Care Excellence; 2014. 
[32] Macmillan. ACE Project on early diagnosis of cancer. 2014. 
[33] Eades C, Ferguson J, O'Carroll R. Public health in community pharmacy: A 
systematic review of pharmacist and consumer views. BMC Public Health. 
2011;11:582. 
18 
 
[34] Department of Health. Pharmacy in England Building on strengths – 
delivering the future. London: The Stationary Office; 2008. 
[35] DH. Healthy lives, healthy people: our strategy for public health in England. 
London: Department of Health; 2010. 
[36] NHS England. Improving health and patient care through community 
pharmacy - a call to action. . London: NHS England; 2013. 
[37] NHS Scotland. Better Health, Better Care: action plan. Edinburgh: The 
Scottish Goverment; 2008. 
[38] Ayorinde AA, Porteous T, Sharma P. Screening for major diseases in 
community pharmacies: a systematic review. The International journal of 
pharmacy practice. 2013;21:349-61. 
[39] Rothman A. "Is there nothing more practical than a good theory?": Why 
innovations and advances in health behavior change will arise if interventions 
are used to test and refine theory. International Journal of Behavioral Nutrition 
and Physical Activity. 2004;1:11. 
 
19 
 
Study/ 
location 
Objective Intervention Population  Setting Outcome 
Berg et al. 
(2001) 
Germany 
Assess feasibility of the 
prostate specific antigen 
(PSA) test strip in the 
framework of 
programme for prostate 
cancer check-ups and 
see if the acceptance 
rates could be improved 
Materials: PSA test strip for EDTA 
whole blood and capillary blood, 
questionnaire, advertisements in 
media 
Cancer Type: Prostate 
Procedures: The test was offered 
free of charge to all men in Jena. An 
extensive information campaign 
accompanied the screening 
programme. Participants were also 
asked to fill in a questionnaire. Test 
results, their meaning and 
limitations, were given both orally 
and in writing. Participants with 
positive results were urged to see 
the study urologist/GP. 
n=2119 men 
(13% of all 
potential 
participants), 
aged 45-75 
years 
Provider: All pharmacies (n=28) 
in Jena. No details given on who 
administered the tests 
Duration: One month 
Measure: Number of tests conducted and 
acceptance toward them 
Result: 2119 tests were completed. Mean number of 
tests per pharmacy was 83. Fifteen percent of the 
tests conducted showed a positive PSA results and 
prostate carcinoma was confirmed in 14 cases 
(0.66%). Incidence rate responds to 650 cases per 
100,000 men tested. Within eight weeks after the 
pilot ended, 23.4% of those tested positive had 
consulted an urologist. Of the 14 cases, nine were 
early stage (T2) and five were clinical stage (T3). The 
test enhanced acceptance rate of prostate cancer 
check-ups but should not be used as a substitute for 
regular physical examinations.  
Boyle et 
al. (2004) 
USA 
Determine whether 
pharmacists using a risk 
assessment tool could 
positively influence 
men's attendance in 
annual physical 
examinations 
Materials: MHRAT screening tool 
Cancer Type: Prostate & colon 
Procedures: Participants completed 
the screening questionnaire in 
pharmacy/at home.  Pharmacist 
discussed the results with the 
participant in a private appointment. 
Participants were randomly assigned 
to control and telephone 
intervention groups. The 
intervention included four follow up 
phone calls by the pharmacist and 
the control group received a phone 
call at eight weeks.  
n=382 men 
aged 25-74 
years 
considered at 
risk or who had 
not recently had 
a physical 
examinations 
Provider: 30 pharmacies 
(urban/rural) selected from 
applicants replying to the 
National Community 
Pharmacist Association (NCPA) 
adverts. Inclusion criteria was 
availability of private 
counselling areas and 
willingness to complete 15h 
training at own expense  
Duration: Maximum of 12 
weeks for each participant 
 
Measure: Number of risk factors identified and 
whether patient attended a physical examination 
Result: Participants were identified to be at risk for 
1194 significant health conditions. The average 
number of health risks was 3.1. Overall 40% were at 
risk for prostate cancer, 24% for colon cancer and 
68% had not received a physical examination for a 
more than a year. Pharmacist recommendation 
encouraged 60% of the men (n=186) to seek an 
appointment with their physician. There was no 
difference between the intervention and control 
group. 
Giles et al. 
(2001) 
USA 
Examine whether 
education programme 
about breast cancer 
screening together with 
breast cancer risk 
assessment provided by 
Materials: Risk assessment 
instrument (the Gail model) 
Cancer Type: Breast 
Procedures: Participants were 
recruited from pharmacies and 
n=188 women 
aged 18 and 
above 
Provider: Community 
pharmacies (n=6) and health 
screening events (n=2) 
Duration: Follow up six months 
after screening 
Measure: Confidence in performing BSE, frequency 
of performing BSE or attending mammogram/CBE 
Result: Of the participants, 15% were considered to 
be at high risk of breast cancer. Adherence to ASC 
guidelines for monthly BSE increased from 31% to 
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community pharmacies 
increases women’s 
confidence in 
performing screening 
practices endorsed by 
the American Cancer 
Society (ACS) 
health screening events during the 
national breast cancer awareness 
month. Each participant completed 
the risk assessment instrument, had 
consultation with a pharmacist and 
received written explanation of 
individual risk factors. All women, 
regardless of their risk category, 
were encouraged by the pharmacist 
to follow guidelines for breast self-
examination (BSE) and clinical breast 
examinations (CBE). Each consenting 
participant was followed up six 
months after screening. 
56% (p.0.001) for all women six months after the 
programme. Initially 31% performed monthly BSE 
which rose to 56% post intervention. For those 
considered high risk the mean number of BSEs 
performed increased from 20% to 60% (p<0.005). 
The mean number of BSEs increased from 2.69 to 
4.09 (p<0.001).  However, 46.7% of women did not 
change the BSE frequency post intervention but 
many of those who did not change frequently were 
already performing monthly BSE. Women’s 
confidence improved from 6.41 to 7.04 (p<0.001).  
The risk assessment and education session by 
pharmacist did not increase the rate of mammogram 
screening for women over 40. 
Giorgio 
Rossi et al. 
(2015) 
Italy 
Evaluate the effect of 
introducing self-
sampling device (mail/ 
pharmacy) on screening 
uptake in comparison to 
standard reminder letter 
Materials: Self-sampling device 
(Delphi Screener) 
Cancer Type: Cervical 
Procedures: The participants were 
allocated to either control group 
(standard reminder) or experimental 
groups (home kit or kit available 
from pharmacy) through randomised 
invitation letters. These were sent 
according to each programmes 
reminder schedule, usually 3 months 
after the initial invitation. Tests 
completed within 3 months of the 
invitation were counted as a success. 
n=14041 
women aged 
30-64 who had 
not responded 
to an earlier 
invitation to 
screening 
Provider: Six different regional 
cervical screening programmes 
were involved. Total of 35 
pharmacies were involved 
across the regions (varying from 
1 to 21 per region) 
Duration: Recruitment 6 
months, follow up 15 months 
Measure: Participation in screening 
Result: Participation to screening was 11.9% in the 
control, 21.6% in home test kit group and 12.0% in 
pharmacy pick up group. Home mailing sampler kit 
was an effective way to increase screening 
participation, effectiveness of pharmacies varied 
from centre to centre. The cervical intraepithelial 
neoplasia grade 2+ (CIN2+) detection rate was low in 
women tested with self-sampling 
Jiwa et al. 
(2009) 
Australia 
Test the two 
interventions for 
identifying people at risk 
of bowel cancer and 
compare referral rates 
Materials: Tick test (based on two 
referral guidelines),  a GP referral 
letter, Patient Consultation 
Questionnaire (PSQ) 
Cancer Type: Bowel 
Procedures: Pharmacy users 
presenting with lower bowel 
symptoms or requesting a product 
that could be used for such 
conditions were recruited. Based on 
n=109 (59 tick 
test, 50 QCP) 
Provider: 16 pharmacies (tick 
test n=8, PCQ n=16) in 
metropolitan Perth.  
Duration: 8 weeks for the tick 
test, month for PCQ plus follow 
up after four weeks 
Measure: Number of people referred to GP 
Result: Tick test: 6 out of 59 were referred to their 
GP and all of these saw their GP 
PCQ:  12 participants were referred to their GP. At 
follow up seven had seen there GP, three were not 
planning to do so and two could not be contacted 
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pharmacy they visited, they 
completed either the tick test or 
PCQ. Participants scoring above 
threshold on tick test were 
encouraged to see their GP and given 
referral letter. PCQ scores were given 
to the participant and sent to their 
nominated GP. Those with persistent 
symptoms or score above threshold 
were encouraged to see their GP. 
Jiwa et al. 
(2011) 
Australia 
To test the deployment 
of self-administered 
questionnaire as an aid 
to advising patients with 
lower bowel symptoms 
 
 
Materials: Patient Consultation 
Questionnaire (PCQ) 
Cancer Type: Bowel 
Procedures: People presenting with 
symptoms/purchasing a product that 
could be used for such conditions 
were consented by the pharmacists 
and given questionnaires to fill in. 
Researcher contacted the 
participants a week later about their 
scores. Participants’ GPs were sent a 
letter with the score. Patients were 
contacted four weeks later if they 
had seen a GP.  
n=91(61 female, 
31 male
2
)  aged 
18-85 
Provider: 21 pharmacies 
Duration: 6 months 
Measure: PSQ score and number of people who 
acted on referral recommendation 
Result: 8 out of 91 (8.7%) were recommended to 
contact their GP as they got a score higher than 50 
on the PCQ and out of those 5 did. Majority of 
people presenting at pharmacies had low PCQ 
scores. The percentage of people scoring 50 or 
higher is lower in pharmacies (8.7%) than in GP 
practices (49.9%). No data on what the outcome of 
the visit to the GP was. 
Levin et al. 
(1997) 
USA 
Evaluate the three 
different tests and 
assess participant and 
physician compliance 
Materials: Non-hydrated Hemoccult, 
rehydrated Hemoccult and 
Hemoccult SENSA test kits 
(containing contained printed 
instructions with dietary restrictions, 
collection papers, applicator sticks, 
free post envelope and 9 FOBTs, 3 of 
each), questionnaire on risk factors 
Cancer Type: Colorectal 
Procedures: Mass media campaign 
on early detection of colorectal 
n=7794 
(m=3376, 
f=4418), 78% 
aged over 50 
Provider: Community 
pharmacies and comminty 
groups in rural area. Staff was 
trained on giving instructions. 
Duration: 4 weeks 
Measure: Number of kits returned, predictive rates 
of the different test kits and cancer incidence 
Result: 13 % of the 85 931 kits distributed were 
returned for processing. Overall 16% positivity rate 
was reported. Positivity rates for different tests 
were: rehydrated hemoccult (15%), hemoccult 
SENSA (7%), nonhydrated hemoccult (5%). The 
positive predictive value was 14% for nonhydrated 
hemoccult, 7% for rehydrated hemoccult and 11% 
for hemoccult SENSA.   
Information on diagnostic follow up was obtained 
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 61+31=92 not 91 
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cancer was run before and during 
the screening campaign. Distribution 
sites were showing a video 
explaining the steps in performing 
the test followed by verbal 
instructions by staff. Trained 
laboratory staff developed the tests. 
Participants were notified of their 
results either by phone or letter. 
Those with positive results were 
called and received a letter. 
Permission was asked for contacting 
their GP about the date and type of 
follow up performed.  
for 943 (70%) of the 1337 participants who tested 
positive. Of those tested positive 59% had a 
colonoscopy or flexible sigmoidoscopy and double 
contrast barium enema examination on follow-up. 
23 participants (2%) were diagnosed as having 
colorectal cancer. Of those diagnosed 20 (87%) were 
detected at an early stage. 
McGuire 
et al. 
(2007) 
USA 
Project utilising 
community pharmacists 
to educate and enrol low 
to moderate income  
and medically 
underserved women 
into a state-wide breast 
and cervical cancer 
screening programme 
Materials: Enrolment packs 
Cancer Type: Breast and cervical 
cancer 
Procedures: Each participating 
pharmacy was given patient 
enrolment packs. After enrolment 
patients received a coupon from 
pharmacy or from Nebraska 
Department of Health (if pharmacy 
was not doing on site enrolment). 
Coupon entitled them to physical 
examination including breast and 
pelvic examination and pap smear). 
n=112 women 
(107 white, 
Hispanic 3, 
African-
American 2), 
median age 48, 
44% referrals 
were for 
women 50  
years of age or 
older 
Provider: 28 pharmacies in 
medically underserved areas 
Duration: Unclear 
Measure: Uptake of referrals from community 
pharmacies to screening 
Result: 112 of the 300 packs distributed to patients 
led to a referral to a doctor. Pharmacists’ gender or 
on-site enrolment of patients did not have major 
effects on enrolment rate. Sites involved in teaching 
pharmacy students and sites who advertised the 
programme in local newspapers were moderately 
more successful in recruiting women to the 
programme. All of the 112 referrals came from 
independent pharmacies. Only two of the referrals 
came from urban pharmacies. 
Park et al. 
(2011) 
South 
Korea 
Identify and address 
barriers to breast cancer 
screening 
Materials: Posters 
Cancer Type: Breast 
Procedures: Multicomponent 
intervention in which one 
component was posters in 
pharmacies 
n=480
3
 women 
aged 30-69 
Provider: Multiple including 
pharmacies 
Duration: 6 months 
Measure: Percentage change in those who believed 
in myths and likelihood of attending mammography 
Result: Posters at pharmacies and clinics were 
associated with reduced ‘big breast means cancer 
myth’.  Street promotion and pharmacy/clinic 
posters associated with reduction in the myth that 
best time to have mammogram is when you have 
symptoms. Posters in waiting rooms significantly 
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 Pre and post intervention groups were independent of each other 
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associated with increased intention of having a 
mammogram. 
Potter et 
al. (2010) 
USA 
Compare the 
effectiveness of two 
different pharmacy 
based colorectal cancer 
screening interventions 
Materials: FOB test (FIT group), 2 
page educational hand out (CRCS 
education group), 16-item survey 
Cancer Type: Colorectal 
Procedures: Participants were 
recruited during influenza 
vaccination sessions.  
FIT group: participants received a 
FOB test with a brief counselling on 
how to use the test and importance 
of screening. The researcher 
contacted the participant and their 
clinician with the test results.  
CRCS education group: participants 
were given the hand out with verbal 
explanation and were encouraged to 
contact their GP for a test kit.  
A reminder call was made to both 
three to six weeks later. Survey was 
conducted three to six months later. 
n=133 age 50-
80 
Provider: 18 pharmacies 
Duration: 2 months during 
annual influenza vaccination 
campaign. 
Measure: Self-reported CRCS activity, comparison of 
CRCS completion rates for the two groups 
Result: 967 people received influenza vaccines 
during the study times. A total of 133 individuals 
were enrolled to the study. The follow up rates were 
90% for FIT group (n=86) and 74%  CRCS education 
group (n=28).  
CRCS group: 67.9% had seen their primary care 
provider by the time of the interview, 50% talked 
specifically about CRCS with their primary care 
person and third had scheduled a test or had already 
completed it.  
FIT group: 32.6% had seen primary care clinicians 
and 19.8% had discussed CRCS with their clinician. 
59.3% (n=51) reported completing CRCS by any 
method at the follow up point, the percentage of 
completed FIT results confirmed to the researchers 
through results was 52.2%. There was one abnormal 
result recorded and that participant reported 
completing diagnostic colonoscopy within two 
months of receiving the screening results.  
 
